Ceribell’s $53 Million Series C Financing

Wilson Sonsini Goodrich & Rosati advised Ceribell on the deal.

Ceribell, innovator of the Rapid Response EEG™, a novel non-invasive brain monitor, announced the completion of a $53 million Series C financing, which was co-led by Longitude Capital and The Rise Fund. Other new investors include RA Capital Management, Redmile Group, and Red Tree Venture Capital, with additional support from existing shareholders.

Ceribell’s technology platform is designed to address the need for faster diagnosis in patients with suspicion of seizure. The company will use the financing proceeds to further expand its commercial footprint in emergency departments and intensive care units globally. In addition, Ceribell will continue to leverage the power of machine learning and easy EEG accessibility for other neurological conditions beyond seizure.

The Wilson Sonsini team included: James Huie (Picture), Daniel Cho, James Kim, Jon Loebl, Lenka Schvaigerova, Jim Heslin, Darby Chan, Josh Gruenspecht, Anne Seymour and Seth Cowell.

Involved fees earner: Darby Chan – Wilson Sonsini Goodrich & Rosati; Daniel Cho – Wilson Sonsini Goodrich & Rosati; Seth Cowell – Wilson Sonsini Goodrich & Rosati; Joshua Gruenspecht – Wilson Sonsini Goodrich & Rosati; James Heslin – Wilson Sonsini Goodrich & Rosati; James Huie – Wilson Sonsini Goodrich & Rosati; James Kim – Wilson Sonsini Goodrich & Rosati; Jon Loebl – Wilson Sonsini Goodrich & Rosati; Anne Seymour – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: Ceribell;

Author: Martina Bellini